Status:

COMPLETED

Early FES Cycling in Acute Spinal Cord Injury for Neuromuscular Preservation and Neurorecovery

Lead Sponsor:

University of Alberta

Collaborating Sponsors:

Royal Alexandra Hospital

Glenrose Foundation

Conditions:

Acute Spinal Cord Injury

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

Spinal cord injury (SCI) is a devastating condition that often leads to paralysis and multiple health problems such as muscle wasting, bone loss and spasticity. Despite the paralysis, functional elect...

Detailed Description

Spinal cord injury (SCI) usually results in weakness or paralysis in the legs and/or arms, depending on the level and severity of the damage to the spinal cord. In addition, people with SCI often deve...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Traumatic or non-traumatic SCI
  • Acute onset of SCI
  • Able to start FES cycling 14-21 days post injury
  • Injury level C1 - L5
  • AIS A, B, C, D (ASIA Impairment Scale)
  • Medically stable
  • Absolute Contraindications and Exclusion Criteria
  • AIS D, able to walk without assistive device
  • Unstable spine fractures
  • Unstable fractures/dislocations in lower extremities or pelvis
  • Pregnancy
  • Unable to give consent to participate in the study
  • Contraindications for TMS (Transcranial Magnetic Stimulation).
  • Relative Contraindications and Exclusion Criteria (Exclusion or Caution)
  • Lower motor neuron injury with insufficient muscle contraction with FES
  • Peripheral nerve or root injury resulting in denervated lower limb muscles
  • History of severe hip or knee instability or dislocation/subluxation
  • Osteoporosis in lower extremities that could result in fracture from cycling
  • Osteoarthritis in lower extremities
  • Limited range of motion in hip and knee preventing cycling
  • History of epilepsy not effectively managed by medication
  • History of heart problems (coronary artery disease / myocardial infarction / congestive heart failure)
  • Implanted cardiac demand pacemaker
  • Implanted stimulators: diaphragmatic, epidural, vagus nerve, phrenic
  • Malignant tumor in stimulated areas
  • Thrombophlebitis or thrombosis in stimulated area
  • Skin lesions or open wounds at any potential electrode site
  • Pressure ulcers that could deteriorate from cycling
  • Spasticity
  • Autonomic dysreflexia
  • Active heterotopic ossification in lower extremities
  • Extreme edema or adipose tissue in legs
  • Any other contraindications to participate in an active exercise program

Exclusion

    Key Trial Info

    Start Date :

    April 21 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    October 31 2023

    Estimated Enrollment :

    35 Patients enrolled

    Trial Details

    Trial ID

    NCT05255679

    Start Date

    April 21 2021

    End Date

    October 31 2023

    Last Update

    September 19 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Alberta

    Edmonton, Alberta, Canada, T6G 2E1